Pharma Focus Asia

ONO Enters into a Development and License Agreement with Numab

Friday, April 01, 2022

Ono Pharmaceutical Co., Ltd., announced that it has exercised its option to enter into a development and license agreement with Numab Therapeutics AG (Waedenswil, Switzerland; CEO, David Urech; “Numab”) for a multispecific antibody candidate in the immuno-oncology area that was generated through a research collaboration between the two companies initiated in 2017.

Under the terms of the license agreement, Ono acquires intellectual property rights and exclusive global development and commercialization rights for a multispecific antibody targeting a novel immuno-oncology target. In consideration for the license agreement, Ono will pay to Numab up to CHF 258 million for upfront fee and milestone payments depending on the development progress, as well as sales achievements including the payments under the research and option agreement executed in 2017. Ono will also pay to Numab tiered single to double digit royalties on future sales.

“We hope that the program candidate generated through our work with Numab will become a therapeutic option for patients with cancer who may benefit from this new treatment modality,” said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono Pharmaceutical. “Through the synergy between Numab’s multispecific antibody platform and Ono’s deep immuno-oncology expertise, we are continuously committed to fueling our diverse drug discovery efforts to advance our immuno-oncology pipeline.”

“We are proud to have advanced this novel multispecific antibody candidate against a new and very challenging immuno-oncology target to this milestone,” said David Urech, Ph.D., Founder and Chief Executive Officer of Numab. “The licensing of the asset is an affirmation of our platform’s ability to create novel and unique pharmacology. We look forward to our continued partnership with Ono as we have been further collaborating on our shared mission of developing next generation immuno-oncology therapeutics for patients with cancer.”

In March 2020, Ono expanded the alliance with Numab by entering into a second research and option agreement to discover and develop a distinct multispecific antibody drug candidates, other than those covered by this agreement, for the treatment of various cancers.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024